

Kavinace Ultra PM

Blend of ingredients shown to improve the onset and quality of sleep*

Item Number	Available Sizes	Serving Size
2083	30 Capsules	1 Capsule






The Science

GABA

GABA is the primary inhibitory neurotransmitter in the brain¹


GABA is important for **calm** and **sleep**^{2,3}

GABA Pathway



** Relative amounts of ingredients as compared to other Kavinace products.


MORE SCIENCE BEHIND KAVINACE ULTRA PM



GABA and sleep

Transitioning between sleep and wake states relies on signaling from sleep- and wake-promoting areas in the brain⁴

- During sleep, GABA and melatonin from sleep-promoting areas of the brain inhibit the release of norepinephrine and histamine from wake-promoting areas⁵
- Conversely, norepinephrine and histamine from wake-promoting areas of the brain inhibit the release of GABA from sleep-promoting areas⁵
- Strengthening GABA and dampening wake-promoting neurotransmission are approaches being used to promote healthy sleep⁵



Kavinace Ultra PM improves sleep

In a randomized, placebo-controlled study, 1 capsule of Kavinace Ultra PM taken at bedtime for 5 days significantly improved quality of sleep as measured by the Pittsburgh Sleep Quality Index (PSQI)6*

Participants taking Kavinace Ultra PM reported:

- Decreased time to fall asleep*
- Increased duration of sleep*
- Decreased sleep disturbances*



Suggested Use: Take 1 capsule at bedtime as needed or as directed by your healthcare provider. Do not exceed suggested use.

mount Per Serv	ring		% D\
lelatonin		3 mg	†
4-amino-3-phen 5-hydroxytryptop <i>simplicifolia</i> seed	han (from <i>Gri</i>		
Daily Value (D)0	not establishe	d	



Gou Z, et al. Dongwuxue Yanjiu. 2012;33(E5-6):E75-81. Mohler H. Neuropharmacology. 2012;62(1):42-53. Saper C, et al. Nature. 2005;437(7063):1257-63.

Consult your healthcare provider before taking with sedatives.



Feeling fatigued and stressed?

Learn more about AdreCor at www.neuroscienceinc.com/products/adrecor

Kunz D and Mahlberg R. J Sleep Res. 2010;19(4):591-6. Holst S, et al. Annu Rev Pharmacol Toxicol. 2016;56:577-603. Data on file, 2011. NeuroScience, Inc., Osceola, WI 54020.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

1 2083KPM30.12

2.